Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)

Giorgino, Francesco; Benroubi, Marian; Jui-Hung Sun; Zimmermann, Alan G.; Pechtner, Valeria; Sun, Jui-Hung
December 2015
Diabetes Care;Dec2015, Vol. 38 Issue 12, p2241
Academic Journal
journal article
Objective: This study compared the efficacy and safety of once-weekly dulaglutide, a glucagon-like peptide-1 receptor agonist, with daily insulin glargine, both combined with maximally tolerated doses of metformin and glimepiride in patients with type 2 diabetes. The primary objective was noninferiority of dulaglutide 1.5 mg to glargine in the HbA1c change from baseline at 52 weeks.Research Design and Methods: In this 78-week, open-label study, 810 patients were randomized to dulaglutide 1.5 mg, dulaglutide 0.75 mg, or glargine.Results: The baseline mean ± SD HbA1c was 8.1 ± 1.0% (65.5 ± 10.8 mmol/mol). The least squares mean ± SE HbA1c change from baseline to the primary end point was -1.08 ± 0.06% (-11.8 ± 0.7 mmol/mol) for dulaglutide 1.5 mg, -0.76 ± 0.06% (-8.3 ± 0.7 mmol/mol) for dulaglutide 0.75 mg, and -0.63 ± 0.06% (-6.9 ± 0.7 mmol/mol) for glargine, with an end point mean ± SD dose of 29 ± 26 units (0.33 ± 0.24 units/kg), and a fasting plasma glucose (mean ± SD) of 118 ± 23 mg/dL from self-monitored plasma glucose. Statistical criteria for superiority were met with dulaglutide 1.5 mg and for noninferiority with dulaglutide 0.75 mg. More patients on dulaglutide 1.5 mg achieved HbA1c targets <7.0% (53 mmol/mol) versus glargine (P < 0.001). Body weight decreased with dulaglutide and increased with glargine. Total hypoglycemia rates were lower with dulaglutide; severe hypoglycemia was minimal. Increases in pancreatic enzymes were observed for dulaglutide. Incidence of nausea (15.4, 7.7, and 1.5%) and diarrhea (10.6, 9.2, and 5.7%) were more common with dulaglutide 1.5 mg and 0.75 mg than with glargine.Conclusions: Once-weekly dulaglutide 1.5 mg, compared with daily insulin glargine without forced titration, demonstrated greater HbA1c reduction and weight loss, with a higher incidence of gastrointestinal adverse events and a lower risk of hypoglycemia.


Related Articles

  • Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date. Howell, Rebecca; Wright, Adrienne M; Clements, Jennifer N // Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy;Apr2019, Vol. 12, p505 

    Metformin is the first-line therapy for the management of type 2 diabetes. After 3 months of metformin, add-on therapy can be considered if an individual's glycemic control has not been achieved for hemoglobin A1c, fasting blood glucose levels, and postprandial blood glucose levels. Liraglutide...

  • Management of Blood Glucose in Type 2 Diabetes Mellitus. RIPSIN, CYNTHIA M.; KANG, HELEN; URRBAN, RANDDALL J. // American Family Physician;1/1/2009, Vol. 79 Issue 1, p29 

    Evidence-based guidelines for the treatment of type 2 diabetes mellitus focus on three areas: intensive lifestyle intervention that includes at least 150 minutes per week of physical activity, weight loss with an initial goal of 7 percent of baseline weight, and a low-fat, reduced-calorie diet;...

  • Controlling diabetes.  // Mayo Clinic Health Letter;Sep2014, Vol. 32 Issue 9, p1 

    The article discusses how to control the disease called diabetes, particularly Type 1 and type 2 diabetes. It cites the importance of controlling blood glucose levels in the long term because extra glucose in the bloodstream will result in such ailments as heart disease, kidney disease, and eye...

  • New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy. Namba, Mitsuyoshi; Katsuno, Tomoyuki; Kusunoki, Yoshiki; Matsuo, Toshihiro; Miuchi, Masayuki; Miyagawa, Jun-ichiro // Clinical & Experimental Nephrology;Feb2013, Vol. 17 Issue 1, p10 

    Incretin-based therapy was first made available for the treatment of type 2 diabetes mellitus (T2DM) in the US in 2006 and in Japan in 2009. Four DPP-4 inhibitors and two GLP-1 analog/receptor agonists are currently available. The effects of incretin-based therapy are assumed to be exerted...

  • Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. Cuthbertson, Daniel J.; Irwin, Andrew; Gardner, Chris J.; Daousi, Christina; Purewal, Tej; Furlong, Niall; Goenka, Niru; Louise Thomas, E.; Adams, Valerie L.; Pushpakom, Sudeep P.; Pirmohamed, Munir; Kemp, Graham J. // PLoS ONE;Dec2012, Vol. 7 Issue 12, p1 

    Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are effective for obese patients with type 2 diabetes mellitus (T2DM) because they concomitantly target obesity and dysglycaemia. Considering the high prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with T2DM, we determined...

  • Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data. Kugler, Anne J; Thiman, Michael L // Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy;May2018, Vol. 11, p187 

    Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist, which has been on the market in the USA since 2014. Dulaglutide has performed well in head-to-head studies against metformin, glargine, and sitagliptin, where its A1c lowering ranged from -0.78% to –1.64% over...

  • Polymorphisms of GLP-1 Receptor Gene and Response to GLP-1 Analogue in Patients with Poorly Controlled Type 2 Diabetes. Lin, Chia-Hung; Lee, Yun-Shien; Huang, Yu-Yao; Hsieh, Sheng-Hwu; Chen, Zih-Syuan; Tsai, Chi-Neu // Journal of Diabetes Research;2/15/2015, Vol. 2015, p1 

    Aim. The relationship between genetic polymorphisms of the glucagon-like peptide-1 (GLP-1) receptor (GLP1R) gene and unresponsiveness to GLP-1 analogue treatment in patients with poorly controlled type 2 diabetes mellitus (DM) is unclear. Methods. Thirty-six patients with poorly controlled type...

  • Sulfonylurea versus metformin in type 2 diabetes.  // CMAJ: Canadian Medical Association Journal;10/7/2014, Vol. 186 Issue 14, p1067 

    The article focuses on a study of patient-important outcomes by comparing sulfonylurea and metformin monotherapy in patients with type 2 diabetes. It noted some effects of sulfonylurea including a decline in the risk of nonfatal macrovascular outcomes and the development of mild and severe...

  • Pramlintide Improved Glycemic Control and Reduced Body Weight in Patients With Type 2 Diabetes Treated With Basal Insulin (Without Mealtime Insulin) and a Thiazolidinedione. Lorenzi, Gayle; Frias, Juan; Lutz, Karen; Kesty, Nicole; Zhang, Bei; Kolterman, Orville // Diabetes;Jun2007 Supplement 1, Vol. 56, pA147 

    Pramlintide (PRAM), an analog of the β-cell hormone amylin, improves glycemic control and body weight in patients with type 2 diabetes (T2DM) treated with insulin with or without sulfonylurea (SFU) and/or metformin (MET). Its efficacy and safety as an adjunct to insulin+thiazolidinedione...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics